Conceptual Framework for Cancer Care During a Pandemic Incorporating Evidence From the COVID-19 Pandemic.


Journal

JCO global oncology
ISSN: 2687-8941
Titre abrégé: JCO Glob Oncol
Pays: United States
ID NLM: 101760170

Informations de publication

Date de publication:
01 08 2022
Historique:
entrez: 2 8 2022
pubmed: 3 8 2022
medline: 5 8 2022
Statut: ppublish

Résumé

With successive infection waves and the spread of more infectious variants, the COVID-19 pandemic continues to have major impacts on health care. To achieve best outcomes for patients with cancer during a pandemic, efforts to minimize the increased risk of severe pandemic infection must be carefully balanced against unintended adverse impacts of the pandemic on cancer care, with consideration to available health system capacity. Cancer Australia's conceptual framework for cancer care during a pandemic provides a planning resource for health services and policy-makers that can be broadly applied globally and to similar pandemics. Evidence on the impact of the COVID-19 pandemic on cancer care and health system capacity to June 2021 was reviewed, and the conceptual framework was developed and updated. Components of health system capacity vary during a pandemic, and capacity relative to pandemic numbers and severity affects resources available for cancer care delivery. The challenges of successive pandemic waves and high numbers of pandemic cases necessitate consideration of changing health system capacity in decision making about cancer care. Cancer Australia's conceptual framework provides guidance on continuation of care across the cancer pathway, in the face of challenges to health systems, while minimizing infection risk for patients with cancer and unintended consequences of delays in screening, diagnosis, and cancer treatment and backlogs because of service interruption. Evidence from the COVID-19 pandemic supports continuation of cancer care wherever possible during similar pandemics. Cancer Australia's conceptual framework, underpinned by principles for optimal cancer care, informs decision making across the cancer care continuum. It incorporates consideration of changes in health system capacity and capacity for cancer care, in relation to pandemic progression, enabling broad applicability to different global settings.

Identifiants

pubmed: 35917484
doi: 10.1200/GO.22.00043
pmc: PMC9470141
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2200043

Références

ESMO Open. 2021 Apr;6(2):100058
pubmed: 33601295
Prev Med. 2021 Oct;151:106585
pubmed: 34217412
Cancer. 2021 May 1;127(9):1459-1468
pubmed: 33378122
Int J Med Inform. 2021 Jul;151:104483
pubmed: 33984625
Cancer Cell. 2020 Nov 9;38(5):629-646
pubmed: 33049215
JAMA Oncol. 2021 Jun 1;7(6):878-884
pubmed: 33914015
Cancer Res Treat. 2021 Jul;53(3):678-684
pubmed: 33421983
Ann Oncol. 2020 Jul;31(7):894-901
pubmed: 32224151
Ecancermedicalscience. 2020 May 18;14:1047
pubmed: 32565900
Prev Med. 2021 Oct;151:106623
pubmed: 34029578
J Clin Oncol. 2021 May 20;39(15):1687-1688
pubmed: 33780268
Prev Med. 2021 Oct;151:106602
pubmed: 34217417
JCO Glob Oncol. 2021 Feb;7:242-252
pubmed: 33571005
Crit Rev Oncol Hematol. 2021 Jul;163:103365
pubmed: 34052423
J Clin Oncol. 2021 Jul 10;39(20):2232-2246
pubmed: 34085538
JCO Glob Oncol. 2020 Jun;6:799-808
pubmed: 32511066
Lancet. 2020 Jun 20;395(10241):1919-1926
pubmed: 32473682
J Clin Oncol. 2020 Jul 1;38(19):2201-2205
pubmed: 32343643
N Engl J Med. 2020 May 21;382(21):2049-2055
pubmed: 32202722
Cancer Biol Med. 2021 Feb 15;18(1):298-307
pubmed: 33628602
Ann Oncol. 2021 Jun;32(6):787-800
pubmed: 33746047
Crit Rev Oncol Hematol. 2021 Nov;167:103273
pubmed: 33737160
JCO Glob Oncol. 2020 Sep;6:1428-1438
pubmed: 32986516
BMC Med. 2020 Oct 16;18(1):329
pubmed: 33066777
Ann Oncol. 2020 Oct;31(10):1320-1335
pubmed: 32745693
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
JCO Oncol Pract. 2020 Aug;16(8):431-434
pubmed: 32463764
Support Care Cancer. 2021 Sep;29(9):5463-5473
pubmed: 33694089
Support Care Cancer. 2020 Aug;28(8):3485-3488
pubmed: 32451702
JAMA Netw Open. 2020 Aug 3;3(8):e2017267
pubmed: 32749465
JCO Oncol Pract. 2020 Aug;16(8):467-482
pubmed: 32401686
Emerg Infect Dis. 2020 Dec;26(12):2844-2853
pubmed: 32985971
JCO Glob Oncol. 2021 Feb;7:311-323
pubmed: 33617304
JAMA Oncol. 2020 Jul 1;6(7):1108-1110
pubmed: 32211820
Lancet Oncol. 2021 Nov;22(11):1507-1517
pubmed: 34624250
Lancet Oncol. 2020 Jul;21(7):893-903
pubmed: 32479790
Support Care Cancer. 2022 Feb;30(2):1003-1006
pubmed: 34626251
Nat Med. 2021 Jun;27(6):964-980
pubmed: 34002090
Int J Nurs Stud. 2021 Feb;114:103811
pubmed: 33352440
Lancet Oncol. 2020 Aug;21(8):1023-1034
pubmed: 32702310
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Expert Rev Anticancer Ther. 2021 Sep;21(9):1055-1066
pubmed: 33970745
Int J Qual Health Care. 2021 Jun 23;33(2):
pubmed: 34059892
Br J Surg. 2020 Oct;107(11):1440-1449
pubmed: 32395848
Lancet Oncol. 2020 Oct;21(10):1309-1316
pubmed: 32853557
J Natl Compr Canc Netw. 2020 Apr 15;:1-6
pubmed: 32294617
Oncologist. 2021 May;26(5):e898-e901
pubmed: 33783099
JCO Glob Oncol. 2020 Sep;6:1461-1471
pubmed: 32997537
J Clin Oncol. 2020 Oct 20;38(30):3538-3546
pubmed: 32795225
JAMA Netw Open. 2021 Mar 1;4(3):e211104
pubmed: 33704472
ESMO Open. 2020 Dec;5(6):e001090
pubmed: 33262203
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
JAMA Oncol. 2021 Feb 1;7(2):220-227
pubmed: 33300956
Chest. 2014 Oct;146(4 Suppl):e17S-43S
pubmed: 25144407
Lancet Gastroenterol Hepatol. 2021 Apr;6(4):304-314
pubmed: 33548185
J Gastrointest Cancer. 2021 Jun;52(2):499-507
pubmed: 33950368
Lancet Oncol. 2020 Jul;21(7):914-922
pubmed: 32539942
JTO Clin Res Rep. 2021 Mar;2(3):100141
pubmed: 33437971
BMJ. 2020 Nov 4;371:m4087
pubmed: 33148535
Br J Cancer. 2021 Apr;124(9):1516-1523
pubmed: 33723386
Science. 2020 Jul 24;369(6502):413-422
pubmed: 32532802
Support Care Cancer. 2021 Jun;29(6):2841-2850
pubmed: 33242162
Cancer Med. 2020 Oct;9(19):7161-7171
pubmed: 32810386
Nat Med. 2020 Aug;26(8):1218-1223
pubmed: 32581323
Heliyon. 2020 Dec;6(12):e05684
pubmed: 33344791
Med J Aust. 2021 Nov 15;215(10):479-484
pubmed: 34689343
ESMO Open. 2021 Feb;6(1):100038
pubmed: 33421735
Cancer Immunol Immunother. 2022 Feb;71(2):373-386
pubmed: 34173850
J Natl Cancer Inst. 2021 Apr 6;113(4):371-380
pubmed: 33136163
Int J Cancer. 2021 Jan 15;148(2):363-374
pubmed: 32683687
CNS Spectr. 2013 Jun;18(3):150-162
pubmed: 23591126
Ann Hematol. 2021 Feb;100(2):383-393
pubmed: 33159569
Blood. 2020 Dec 17;136(25):2881-2892
pubmed: 33113551
J Immunother Cancer. 2021 Jan;9(1):
pubmed: 33468556
J Natl Cancer Inst. 2021 Aug 2;113(8):955-961
pubmed: 33367655
Ther Adv Med Oncol. 2020 Nov 02;12:1758835920968463
pubmed: 33224275
JCO Glob Oncol. 2021 Mar;7:416-424
pubmed: 33784177
Ann Am Thorac Soc. 2021 Mar;18(3):408-416
pubmed: 33202144

Auteurs

Vivienne Milch (V)

Cancer Australia, Sydney, New South Wales, Australia.
The University of Notre Dame, Sydney, New South Wales, Australia.

Anne E Nelson (AE)

Evidence Review Contractor, Sydney, New South Wales, Australia.

Melissa Austen (M)

Cancer Australia, Sydney, New South Wales, Australia.

Debra Hector (D)

Cancer Australia, Sydney, New South Wales, Australia.

Scott Turnbull (S)

Cancer Australia, Sydney, New South Wales, Australia.

Rahul Sathiaraj (R)

Cancer Australia, Sydney, New South Wales, Australia.

Carolyn Der Vartanian (C)

Cancer Australia, Sydney, New South Wales, Australia.

Rhona Wang (R)

Cancer Australia, Sydney, New South Wales, Australia.

Cleola Anderiesz (C)

Centre for Health Policy, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.
National Breast Cancer Foundation, Sydney, New South Wales, Australia.

Dorothy Keefe (D)

Cancer Australia, Sydney, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH